Cardiovascular Disease, Hypogonadism and Erectile Dysfunction: Early Detection, Prevention and the Positive Effects of Long-Term Testosterone Treatment: Prospective Observational, Real-Life Data

References

• Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363(2):123–135. doi:10.1056/NEJMoa0911101
   PubMed Web of Science ®Google Scholar
• Livingston M, Kalansooriya A, Hartland AJ, Ramachandran S, Heald A. Serum testosterone levels in male hypogonadism: why and when to check-A review. Int J Clin Pract. 2017;71(11). doi:10.1111/ijcp.12995
   Web of Science ®Google Scholar
• Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2002;87(2):589–598. doi:10.1210/jcem.87.2.8201
   PubMed Web of Science ®Google Scholar
• Zarotsky V, Huang MY, Carman W, et al. Systematic literature review of the risk factors, comorbidities, and consequences of hypogonadism in men. Andrology. 2014;2(6):819–834. doi:10.1111/andr.274
   PubMed Web of Science ®Google Scholar
• Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating NL, Van Hemelrijck M. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol. 2015;68(3):386–396. doi:10.1016/j.eururo.2014.11.039
   PubMed Web of Science ®Google Scholar
• Mazzola CR, Mulhall JP. Impact of androgen deprivation therapy on sexual function. Asian J Androl. 2012;14(2):198–203. doi:10.1038/aja.2011.106
   PubMed Web of Science ®Google Scholar
• Gandaglia G, Briganti A, Jackson G, et al. A Systematic review of the association between erectile dysfunction and cardiovascular disease. Eur Urol. 2014;65(5):968–978. doi:10.1016/j.eururo.2013.08.023
   PubMed Web of Science ®Google Scholar
• Kapoor D, Clarke S, Channer KS, Jones TH. Erectile dysfunction is associated with low bioactive testosterone levels and visceral adiposity in men with type 2 diabetes. Int J Androl. 2007;30(6):500–507. doi:10.1111/j.1365-2605.2007.00744.x
   PubMedGoogle Scholar
• Gazzaruso C, Giordanetti S, De Amici E, et al. Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated type 2 diabetic patients. Circulation. 2004;110(1):22–26. doi:10.1161/01.CIR.0000133278.81226.C9
   PubMed Web of Science ®Google Scholar
• Montorsi F, Briganti A, Salonia A, et al. Erectile Dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol. 2003;44(3):360–365. doi:10.1016/S0302-2838(03)00305-1
   PubMed Web of Science ®Google Scholar
• Montorsi P, Ravagnani PM, Galli S, et al. Association between erectile dysfunction and coronary artery disease: matching the right target with the right test in the right patient. Eur Urol. 2006;50(4):721–731. doi:10.1016/j.eururo.2006.07.015
   PubMed Web of Science ®Google Scholar
• Hodges LD, Kirby M, Solanki J, O’Donnell J, Brodie DA. The temporal relationship between erectile dysfunction and cardiovascular disease. Int J Clin Pract. 2007;61(12):2019–2025. doi:10.1111/j.1742-1241.2007.01629.x
   PubMed Web of Science ®Google Scholar
• Inman BA, St. Sauver JL, Jacobson DJ, et al. A population-based, longitudinal study of erectile dysfunction and future coronary artery disease. Mayo Clinic Proce. 2009;84(2):108–113. doi:10.4065/84.2.108
   PubMed Web of Science ®Google Scholar
• Montorsi P, Ravagnani PM, Galli S, et al. Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: the COBRA trial. Eur Heart J. 2006;27(22):2632–2639. doi:10.1093/eurheartj/ehl142
   PubMed Web of Science ®Google Scholar
• Isidori AM, Buvat J, Corona G, et al. A critical analysis of the role of testosterone in erectile function: from pathophysiology to treatment-a systematic review. Eur Urol. 2014;65(1):99–112. doi:10.1016/j.eururo.2013.08.048
   PubMed Web of Science ®Google Scholar
• Jones TH. Testosterone deficiency: a risk factor for cardiovascular disease? Trends Endocrinol Metab. 2010;21(8):496–503. doi:10.1016/j.tem.2010.03.002
   PubMed Web of Science ®Google Scholar
• Corona G, Monami M, Boddi V, et al. Low Testosterone is Associated with an Increased Risk of MACE Lethality in Subjects with Erectile Dysfunction. J Sex Med. 2010;7(4pt1):1557–1564. doi:10.1111/j.1743-6109.2009.01690.x
   PubMedGoogle Scholar
• Feldman HA, Johannes CB, Derby CA, et al. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts male aging study. Prev Med. 2000;30(4):328–338. doi:10.1006/pmed.2000.0643
   PubMed Web of Science ®Google Scholar
• Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab. 2004;89(7):3313–3318. doi:10.1210/jc.2003-031069
   PubMed Web of Science ®Google Scholar
• Malkin CJ, Pugh PJ, Morris PD, et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart. 2004;90(8):871–876. doi:10.1136/hrt.2003.021121
   PubMed Web of Science ®Google Scholar
• Mathur A, Malkin C, Saeed B, Muthusamy R, Jones TH, Channer K. Long-term benefits of testosterone replacement therapy on angina threshold and atheroma in men. Eur J Endocrinol. 2009;161(3):443–449. doi:10.1530/EJE-09-0092
   PubMed Web of Science ®Google Scholar
• Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154(6):899–906. doi:10.1530/eje.1.02166
   PubMed Web of Science ®Google Scholar
• Heufelder AE, Saad F, Bunck MC, Gooren L. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl. 2009;30(6):726–733. doi:10.2164/jandrol.108.007005
   PubMedGoogle Scholar
• Cornoldi A, Caminiti G, Marazzi G, et al. Effects of chronic testosterone administration on myocardial ischemia, lipid metabolism and insulin resistance in elderly male diabetic patients with coronary artery disease. Int J Cardiol. 2010;142(1):50–55. doi:10.1016/j.ijcard.2008.12.107
   PubMed Web of Science ®Google Scholar
• Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf). 2010;73(5):602–612. doi:10.1111/j.1365-2265.2010.03845.x
   PubMed Web of Science ®Google Scholar
• Sesti F, Pofi R, Minnetti M, Tenuta M, Gianfrilli D, Isidori AM. Late-onset hypogonadism: reductio ad absurdum of the cardiovascular risk-benefit of testosterone replacement therapy. Andrology. 2020;8(6):1614–1627. doi:10.1111/andr.12876
   PubMed Web of Science ®Google Scholar
• Hackett G, Cole N, Mulay A, Strange RC, Ramachandran S. Long-term testosterone therapy in type 2 diabetes is associated with decreasing waist circumference and improving erectile function. World J Mens Health. 2020;38(1):68–77. doi:10.5534/wjmh.180052M
   PubMedGoogle Scholar
• Permpongkosol S, Khupulsup K, Leelaphiwat S, Pavavattananusorn S, Thongpradit S, Petchthong T. Effects of 8-year treatment of long-acting testosterone undecanoate on metabolic parameters, urinary symptoms, bone mineral density, and sexual function in men with late-onset hypogonadism. J Sex Med. 2016;13(8):1199–1211. doi:10.1016/j.jsxm.2016.06.003
   PubMed Web of Science ®Google Scholar
• Giltay EJ, Tishova YA, Mskhalaya GJ, Gooren LJ, Saad F, Kalinchenko SY. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. J Sex Med. 2010;7(7):2572–2582. doi:10.1111/j.1743-6109.2010.01859.x
   PubMed Web of Science ®Google Scholar
• Saad F, Caliber M, Doros G, Haider KS, Haider A. Long-term treatment with testosterone undecanoate injections in men with hypogonadism alleviates erectile dysfunction and reduces risk of major adverse cardiovascular events, prostate cancer, and mortality. Aging Male. 2020;23(1):81–92. doi:10.1080/13685538.2019.1575354
   PubMed Web of Science ®Google Scholar
• Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology. 1999;54(2):346–351. doi:10.1016/S0090-4295(99)00099-0
   PubMed Web of Science ®Google Scholar
• Rosen RC, Cappelleri JC, Gendrano N. The International Index of Erectile Function (IIEF): a state-of-the-science review. Int J Impot Res. 2002;14(4):226–244. doi:10.1038/sj.ijir.3900857
   PubMed Web of Science ®Google Scholar
• English KM, Steeds RP, Jones TH, Diver MJ, Channer KS. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation. 2000;102(16):1906–1911. doi:10.1161/01.CIR.102.16.1906
   PubMed Web of Science ®Google Scholar
• Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR. Low serum testosterone and mortality in male veterans. Arch Intern Med. 2006;166(15):1660–1665. doi:10.1001/archinte.166.15.1660
   PubMedGoogle Scholar
• Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur j Endocrinol. 2013;169(6):725–733. doi:10.1530/EJE-13-0321
   PubMed Web of Science ®Google Scholar
• Svartberg J, von Mühlen D, Schirmer H, Barrett-Connor E, Sundfjord J, Jorde R. Association of endogenous testosterone with blood pressure and left ventricular mass in men. The Tromsø Study. Eur j Endocrinol. 2004;150(1):65–71. doi:10.1530/eje.0.1500065
   PubMed Web of Science ®Google Scholar
• Kelly DM, Jones TH. Testosterone: a vascular hormone in health and disease. J Endocrinol. 2013;217(3):R47–71. doi:10.1530/JOE-12-0582
   PubMed Web of Science ®Google Scholar
• Hougaku H, Fleg JL, Najjar SS, et al. Relationship between androgenic hormones and arterial stiffness, based on longitudinal hormone measurements. Am J Physiol Endocrinol Metab. 2006;290(2):E234–242. doi:10.1152/ajpendo.00059.2005
   PubMed Web of Science ®Google Scholar
• Saad F, Haider A, Doros G, Traish A. Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss. Obesity. 2013;21(10):1975–1981. doi:10.1002/oby.20407
   PubMed Web of Science ®Google Scholar
• Saad F, Yassin A, Doros G, Haider A. Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: observational data from two registry studies. Int j Obesity. 2016;40(1):162–170. doi:10.1038/ijo.2015.139
   PubMed Web of Science ®Google Scholar
• Sai Ravi Shanker A, Phanikrishna B. Association between erectile dysfunction and coronary artery disease and its severity. Indian Heart J. 2013;65(2):180–186. doi:10.1016/j.ihj.2013.02.013
   PubMedGoogle Scholar
• Almehmadi Y, Yassin DJ, Yassin AA. Erectile dysfunction is a prognostic indicator of comorbidities in men with late onset hypogonadism. Aging Male. 2015;18(3):186–194. doi:10.3109/13685538.2015.1046044
   PubMed Web of Science ®Google Scholar
• Traish AM, Haider A, Haider KS, Doros G, Saad F. Long-Term testosterone therapy improves cardiometabolic function and reduces risk of cardiovascular disease in men with hypogonadism: a real-life observational registry study setting comparing treated and untreated (control) groups. J Cardiovasc Pharmacol Ther. 2017;22(5):414–433.
   PubMed Web of Science ®Google Scholar
• Hoyos CM, Yee BJ, Phillips CL, Machan EA, Grunstein RR, Liu PY. Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnoea: a randomised placebo-controlled trial. Eur j Endocrinol. 2012;167(4):531–541. doi:10.1530/EJE-12-0525
   PubMed Web of Science ®Google Scholar
• Solomon H, Man JW, Jackson G. Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. Heart. 2003;89(3):251. doi:10.1136/heart.89.3.251
   PubMed Web of Science ®Google Scholar
• Ponholzer A, Temml C, Obermayr R, Wehrberger C, Madersbacher S. Is Erectile Dysfunction an Indicator for Increased Risk of Coronary Heart Disease and Stroke? Eur Urol. 2005;48(3):512–518. doi:10.1016/j.eururo.2005.05.014
   PubMed Web of Science ®Google Scholar
• Yassin AA, Nettleship JE, Almehmadi Y, Yassin D-J, El Douaihy Y, Saad F. Is there a relationship between the severity of erectile dysfunction and the comorbidity profile in men with late onset hypogonadism? Arab J Urol. 2015;13(3):162–168. doi:10.1016/j.aju.2015.06.003
   PubMed Web of Science ®Google Scholar
• Saad F, Gooren LJ, Haider A, Yassin A. A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. J Androl. 2008;29(1):102–105. doi:10.2164/jandrol.107.002774
   PubMedGoogle Scholar
• Jones TH, Saad F. The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. Atherosclerosis. 2009;207(2):318–327. doi:10.1016/j.atherosclerosis.2009.04.016
   PubMed Web of Science ®Google Scholar
• Jones TH. Testosterone replacement therapy. Br j Hospital Med. 2007;68(10):547–553. doi:10.12968/hmed.2007.68.10.27326
   Web of Science ®Google Scholar
• Corona G, Maseroli E, Rastrelli G, et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf. 2014;13(10):1327–1351. doi:10.1517/14740338.2014.950653
   PubMed Web of Science ®Google Scholar
• Yassin A, Nettleship JE, Talib RA, Almehmadi Y, Doros G. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters. Aging Male. 2016;19(1):64–69. doi:10.3109/13685538.2015.1126573
   PubMed Web of Science ®Google Scholar
• Yassin A, Almehmadi Y, Saad F, Doros G, Gooren L. Effects of intermission and resumption of long-term testosterone replacement therapy on body weight and metabolic parameters in hypogonadal in middle-aged and elderly men. Clin Endocrinol (Oxf). 2016;84(1):107–114. doi:10.1111/cen.12936
   PubMed Web of Science ®Google Scholar
• Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. J Sex Med. 2013;10(6):1612–1627. doi:10.1111/jsm.12146
   PubMed Web of Science ®Google Scholar
• Corona G, Rastrelli G, Monami M, et al. Body Mass index regulates hypogonadism‐associated cv risk: results from a cohort of subjects with erectile dysfunction. J Sex Med. 2011;8(7):2098–2105. doi:10.1111/j.1743-6109.2011.02292.x
   PubMed Web of Science ®Google Scholar
• Corona G, Rastrelli G, Maseroli E, et al. Low testosterone syndrome protects subjects with high cardiovascular risk burden from major adverse cardiovascular events. Andrology. 2014;2(5):741–747. doi:10.1111/j.2047-2927.2014.00241.x
   PubMed Web of Science ®Google Scholar
• Saad F, Yassin A. Effects of interrupting and resuming long-term testosterone replacement therapy (TRT) with testosterone undecanoate injections (TU) on erectile dysfunction (ED) and anthropometric parameters in hypogonadal men in an observational registry study. J Sexual Med. 2015;12:402.
   Web of Science ®Google Scholar